Pharmaceutical intermediates are chemical composites which form the building blocks of active pharmaceutical ingredient (API). These intermediates are produced as a by-product during the production of API. They are used in the production of bulk drugs and also for research and development (R&D) purpose by various pharma and biopharma companies. There are several kinds of pharmaceutical intermediates, such as vitamin intermediates, cephalosporin intermediates, steroid intermediates, quinolones intermediates etc.
According to study, “Global Pharmaceutical Intermediates Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024” the key companies operating in the global pharmaceutical intermediates market are Lonza, Patheon, Catalent, Ganesh, Jubilant, BASF, Granules, Lianhetech, Chemcon Specialty Chemicals Pvt. Ltd., A.R. Life Sciences Private Limited, Dishman Group, Vertellus Holdings LLC, Midas Pharma GmbH, Aceto Corporation, Codexis, Inc., Cycle Pharma, Sanofi Winthrop Industrie S.A., Dextra Laboratories Ltd., ZCL Chemicals Ltd., Jiujiujiu, Porton, Jiuzhou, ABA Chem, Yongtai, Tianma, Alpha, Easter Chemical Corporation. The key manufacturers are taking effective measures to address lacks of generic drugs. Manufacturers are also focused on their efforts in gaining EMA (European Medicine Agency) or FDA (Food and Drug Administration) approvals for their manufacturing plants.
Based on type, pharmaceutical intermediates market is segmented into good manufacturing practice (GMP) and Non-GMP. Based on structure building blocks, market is segmented into chiral building blocks, achiral building blocks and others. Based on sales channel, market is segmented into distributor channels and direct channel. Based on application, market is segmented into antipyretic analgesics, antibiotics, vitamins, and others. In addition, based on end-users, market is segmented into research labs, contract manufacturing organizations, pharmaceutical companies and others.
The pharmaceutical intermediates market is driven by increase in research & development (R&D) activities, followed by surge in burden of various diseases, presence of major market players, increase in rate of seeking treatment, improved rate of early diagnosis, rise in trend towards new high tech therapeutics, growth in technological advancements, rise in number of promising avenues in the pharmaceutical industries, increase in number of contract manufacturing organizations, rise in demand for generic drugs, and growth in innovation of new products. However, stringent regulatory policies may impact the market. Moreover, rise in government initiatives and presence of various players in the emerging nations are key opportunities for market.
Based on geography, the North-American region holds major share in pharmaceutical intermediates market owing to rise in investments on R&D activities, increase in public health awareness, and rise in incidence of neurological & cardiovascular diseases, and growth in spend on drug making activities by various globally prominent pharmaceutical companies in the region. The European and Asian-Pacific regions are estimated to witness significant growth rate due to rapid improvements in medical infrastructure and increase in rate of patients seeking treatments & global pandemics for instance H1N1, Ebola, and others over the forecast period. It is predicted that the market will be reached at rapid pace because of growth in prevalence of chronic & lifestyle-driven diseases during the forecast period. The global market is projected to register 6.1% CAGR to reach US $ 38,457.2 million by the end of 2024.
For More Information On The Research Report, Refer To Below Link:-
Related Reports by Ken Research:-
Ankur Gupta, Head Marketing & Communications